Investigating Neutrophil Extracellular Traps in Systemic Sclerosis
Neutrophil Extracellular Traps in Systemic Sclerosis
This study is trying to understand how certain immune cells called Neutrophil Extracellular Traps might be linked to the symptoms and complications of Systemic Sclerosis in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 260 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | CHU de Reims Academic / other |
| Locations | 1 site (Reims) |
| Trial ID | NCT06462768 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the role of Neutrophil Extracellular Traps (NETs) in patients with Systemic Sclerosis (SSC) and other connective tissue diseases. It will involve recruiting 100 SSC patients, 30 patients with other connective tissue diseases, and 130 healthy volunteers from the university hospital of Reims. Blood samples will be collected to analyze plasma, serum, and neutrophils to assess NET production and composition in relation to various complications and phenotypes of SSC. The study seeks to clarify the involvement of NETs in the pathogenesis of SSC and their potential correlation with disease manifestations.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with Systemic Sclerosis or other connective tissue diseases who are receiving care at the university hospital of Reims.
Not a fit: Patients with a history of autoimmune systemic or chronic inflammatory diseases, or those with current or past neoplastic diseases, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of the mechanisms underlying Systemic Sclerosis and lead to improved diagnostic and therapeutic strategies.
How similar studies have performed: While the role of NETs in other autoimmune diseases has been explored, this specific investigation in Systemic Sclerosis is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \*For patients of group 1: * Patients with systemic sclerosis (ACR-EULAR Criteria) * Patients taking care of in internal medicine or in dermatology department's of the university hospital of Reims * Patients consenting to participate to the study * Patients enrolled in the national healthcare insurance program For patients of group 2: * Patients with other connective tissue disease (ACR specific-disease criteria) * Patients taking care of in internal medicine or in dermatology department's of the university hospital of Reims * Patients consenting to participate to the study * Patients enrolled in the national healthcare insurance program For patients of group 3 (healthy volunteers) * Patients eligible for blood donation (blood donation regulation criteria of January 11th 2022 decree) * Patients without medical history of autoimmune systemic or chronic inflammatory systemic disease, * Patients without current or past neoplasy disease, * Patients without chronic metabolic pathology * Patients without treatment by anti inflammatory or corticotherapy for the last 15 days, * Patients without infectious pathology or inflammatory acute for the last 15 days * Patients consenting to participate to the study Exclusion Criteria for patients of all groups: * Patients/Healthy volunteers under 18 years old * Patients/Healthy volunteers protected by the law * Patients/Healthy volunteers not consenting to participate to the study after information * Patients with inflammatory pathology or infectious acute intercurrent pathology in the last 15 days before inclusion * Pregnant or breastfeeding women
Where this trial is running
Reims
- Chu Reims — Reims, France (Recruiting)
Study contacts
- Study coordinator: Kevin DIDIER, Dr.
- Email: kdidier@chu-reims.fr
- Phone: 03.26.83.24.44
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.